Transgenic bovines capable of human antibody production

• US 7,414,170 B2
• Filed: 05/19/2003
• Issued: 08/19/2008
• Est. Priority Date: 11/19/1999
• Status: Expired due to Fees

• Current Assignee: Kyowa Hakko Kirin Company Limited (Kirin Holdings Company Limited)
• Original Assignee: Kirin Beer Kabushiki Kaisha
• Inventors: Kuroiwa, Yoshimi, Goldsby, Richard A., Tomizuka, Kazuma, Ishida, Isao, Robl, James M., Kasinathan, Poothappillai, Osborne, Barbara
• Primary Examiner(s): Crouch; Deborah
• Application Number:
  US10/441,503
• Publication Number:
  US 20040068760A1
• Time in Patent Office: 1,919 Days
• Field of Search: 800 14- 17, 800/24, 800/6, 800/5, 800/25, 435/325
• US Class Current: 800/15
• CPC Class Codes: A01K 2207/15 Humanized animals
• CPC Class Codes: A01K 2217/00 Genetically modified animals
• CPC Class Codes: A01K 2267/01 Animal expressing industrially exogenous proteins
• CPC Class Codes: A01K 67/0273 Cloned vertebrates
• CPC Class Codes: A01K 67/0275 Genetically modified vertebrates, e.g. transgenic
• CPC Class Codes: A01K 67/0278 Knock-in vertebrates, e.g. humanised vertebrates
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/42 against immunoglobulins
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C12N 15/8509 for producing genetically modified animals, e.g. transgenic
• CPC Class Codes: C12N 15/8771 Bovine embryos
• CPC Class Codes: C12N 2799/025 where the vector is derived from a parvovirus
• CPC Class Codes: C12N 2800/208 of mammalian origin, e.g. minichromosome

Abstract

The invention features novel methods for the production of large quantities of xenogenous antibodies, such as human antibodies. Preferably, this result is effected by inactivation of IgM heavy chain expression and, optionally, by inactivation of Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of xenogenous antibodies (e.g., non-bovine antibodies), preferably human antibodies.

Claims

1. A transgenic bovine whose genome comprises a mutation in an endogenous immunoglobulin (Ig) heavy chain or Ig light chain locus, said mutation reducing the expression of said Ig heavy chain or Ig light chain.

2. The bovine of claim 1, wherein said mutation reduces the expression of functional IgM heavy chain.

3. The bovine of claim 1, wherein said mutation substantially eliminates the expression of said Ig heavy chain or said Ig light chain.

4. The bovine of claim 1, wherein said mutation is hemizygous.

5. The bovine of claim 1, wherein said mutation is homozygous.

6. The bovine of claim 5, wherein each allele comprises the same antibiotic resistance gene.

7. The bovine of claim 5, wherein each allele comprises a different antibiotic resistance gene.

8. The bovine of claim 1, wherein said mutation is an insertion of a positive selection marker into said endogenous locus.

9. The bovine of claim 8, wherein said positive selection marker is an antibiotic resistance gene.

10. The bovine of claim 8, wherein said positive selection marker is operably linked to a xenogenous promoter.

11. The bovine of claim 1, wherein said mutation is an insertion of a transcription termination sequence into said endogenous loci.

12. The bovine of claim 11, wherein said transcription termination sequence is inserted downstream of the initial ATG codon in exon 2 of an endogenous mu heavy chain locus.

13. The bovine of claim 1, comprising one or more nucleic acids comprising one or more transgenes and expressing an mRNA or protein encoded by saks transgene(s).

14. The bovine of claim 1, the cells of said bovine further comprising one or more chromosomal fragments comprising one or more, all or part of an unrearranged xenogenous chain Ig locus, which undergoes rearrangement and expresses one or more xenogenous Ig molecules in B-cells.

15. The bovine of claim 14, wherein said molecule is an antibody protein.

16. The bovine of claim 15, wherein said xenogenous antibody protein is a human antibody protein.

17. An isolated bovine somatic cell comprising a mutation in an endogenous immunoglobulin (Ig) heavy chain or Ig light chain locus, said mutation reducing the expression of said Ig heavy chain or Ig light chain.

18. The cell of claim 17, comprising a mutation in both alleles of said IgM heavy chain or said light chain.

19. The cell of claim 17, further comprising one or more chromosomal fragments comprising one or more, all or part of a xenogenous Ig locus.

20. The cell of claim 17, wherein said cell is a fetal fibroblast or a B-cell.

21. The cell of claim 17, wherein said mutation is a trapscription termination sequence.

22. The somatic cell of claim 21, wherein said transcription termination sequence is inserted downstream of the initial ATG codon in exon 2 of an endogenous mu heavy chain locus.

32. A method for producing a transgenic bovine having reduced expression of an endogenous Ig heavy chain or Ig light chain locus, said method comprising the steps of:

(a) incubating a permeabilized cell of claim 17 in an extract from a mitotic somatic cell or oocyte under conditions that allow chromatin condensation and nuclear envelope breakdown in said permeabilized cell;

(b) inserting said cell formed in step (a) into a nucleated or enucleated bovine oocyte, thereby forming a reconstituted oocyte; and

(c) transferring said reconstituted oocyte or an embryo formed from said reconstituted oocyte into the uterus of a host bovine under conditions that allow said reconstituted oocyte or said embryo to develop into a fetus.

33. The method of claim 32, wherein, prior to step (b), said cell is incubated under conditions that allow the membrane of said cell to reseal.

34. The method of claim 32, wherein said cell is purified from said extract prior to insertion into said oocyte.

35. The method of claim 32, wherein said fetus develops into a viable offspring.

36. The method of claim 35, further comprising mating two offspring to produce a transgenic bovine whose genome comprises mutations in both alleles of an endogenous immunoglobulin (Ig) heavy chain or Ig light chain locus.

37. The method of claim 32, wherein said oocyte from step (b) is cultured under conditions that allow cell division and one of the resulting cells is recloned one or more times.

38. The method of claim 32, wherein said permeabilized cell and said Qocyte are from the same species.

39. The method of claim 32, wherein said permeabilized cell is a fibroblast, epithelial cell, neural cell, epidermal cell, keratinocyte, hematopoictic cell, melanocyte, chondrocyte, macrophage, monocyte, fibroblast, muscle cell, embryonic stem cell, embryonic germ cell, fetal cell, placental cell, a cell of the female reproductive system, or embryonic cell.

23. A method of producing antibodies, said method comprising the steps of:

(a) administering one or more antigens of interest to a bovine whose genome comprises a mutation in an endogenous immunoglobulin (Ig) heavy chain or Ig light chain locus and the cells of said bovine further comprising a chromosomal fragment or fragments comprising an unrearranged human light chain locus and an unrearranged human heavy chain locus, wherein the loci undergo rearrangement resulting in the production of human antibody proteins specific for said one or more antigens; and

(b) recovering said human antibodies from said bovine.

24. The method of claim 23 wherein said mutation is an insertion of a transcription termination sequence into said endogenous locus.

25. The method of claim 24, wherein said transcription termination sequence is inserted downstream of the initial ATG codon in exon 2 of an endogenous mu heavy chain locus.

27. The method of claims 23 or 26, wherein said antibodies are polyclonal.

28. The method of claims 23 or 26, wherein said antibodies are recovered from the serum of said bovine.

26. A method of producing antibodies, said method comprising recovering human antibodies from a bovine whose genome comprises a mutation in an endogenous immunoglobulin (Ig) heavy chain or Ig light chain locus and the cells of said bovine further comprising a chromosomal fragment comprising a human antibody gene locus, wherein said locus undergo rearrangement resulting in the production of human antibodies.

29. The method of claim 26, wherein said antibodies are directed against a desired antigen.

30. The method of claim 26, wherein said mutation is a transcription termination sequence.

31. The method of claim 30, wherein said transcription termination sequence is inserted downstream of the initial ATG codon in exon 2 of an endogenous mu heavy chain locus.